Rani Therapeutics Holdings, a clinical-stage biotherapeutics company specializing in oral delivery of biologics, announced its management team will participate in a fireside chat at the Chardan Healthcare Conference on October 20, 2026. The event will feature CEO Talat Imran, CFO Nicholas Maestas, and Chief Business Officer Kate McKinley discussing the company's innovative RaniPill® capsule technology, which aims to replace injections with oral dosing. Investors can watch the live webcast on Rani Therapeutics' website, with a replay available after the presentation. This participation highlights the company's ongoing efforts to advance oral biologic therapies and engage with the investment community.
Rani Therapeutics' upcoming participation in the Chardan Healthcare Conference coincides with a challenging day for health-sector stocks on Pluang. As of Oct 14, 2026 03:02 WIB, only 28 of 128 priced health-sector US stocks rose while 100 fell. Notable movers include ERAS at USD 14.78 with a 1-day change of -4.40% and 100% sell order activity, VRTX at USD 485.08 down 4.32% with a nearly balanced buy/sell split, and RXRX at USD 3.84 down 4.24% with strong buy interest at 93%.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
